Evidence-Based Practice: Temozolomide Beyond Glioblastoma

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Current Oncology Reports

• Publication date

  2019-03-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11912-019-0783-5PMID 30835007
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Central Nervous System Cancers, Version 3.2020

  2020cited by this paper
• Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas

  2018cited by this paper
• Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status

  2018cited by this paper
• Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.

  2018cited by this paper
• The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

  2018cited by this paper
• Grade II and III Oligodendroglioma and Astrocytoma.

  2018cited by this paper
• Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma

  2018cited by this paper
• Adult Pilocytic Astrocytoma: An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence.

  2018cited by this paper
• Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics

  2018cited by this paper
• Potent antitumor efficacy of anti-GD2 CAR T-cells in H3K27M+ diffuse midline gliomas

  2018cited by this paper
• Chemotherapy of Oligodendrogliomas.

  2018cited by this paper
• Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen

  2018cited by this paper
• Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial

  2018cited by this paper
• BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

  2018cited by this paper
• ACTR-02. NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS

  2018cited by this paper
• Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma

  2017cited by this paper
• Immune checkpoint blockade for hematologic malignancies: a review.

  2017cited by this paper
• Survival rates and prognostic predictors of high grade brain stem gliomas in childhood: a systematic review and meta-analysis

  2017cited by this paper
• Diffuse Infiltrating Oligodendroglioma and Astrocytoma.

  2017cited by this paper
• Bispecific antibodies for cancer therapy: A review

  2017cited by this paper
• Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

  2017cited by this paper
• Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

  2017cited by this paper
• External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry

  2017cited by this paper
• Optimal Therapies for Newly Diagnosed Elderly Patients with Glioblastoma

  2017cited by this paper
• Anaplastic pleomorphic xanthoastrocytoma with disseminated growth pattern at the time of diagnosis as well as after treatment: case report and review of literature

  2017cited by this paper
• The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

  2016cited by this paper
• Pleomorphic Xanthoastrocytoma with Anaplastic Features in the Tectal Region in a Young Adult Patient: A Case Report.

  2016cited by this paper
• Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.

  2016cited by this paper
• Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

  2016cited by this paper
• Chemotherapy for intracranial ependymoma in adults

  2016cited by this paper
• Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma

  2016cited by this paper
• Pilocytic astrocytoma: pathology, molecular mechanisms and markers

  2015cited by this paper
• Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.

  2015cited by this paper
• Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?

  2015cited by this paper
• MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

  2015cited by this paper
• Adult brainstem gliomas: Correlation of clinical and molecular features.

  2015cited by this paper
• Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.

  2014cited by this paper
• Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.

  2014cited by this paper
• Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma

  2014cited by this paper
• Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.

  2013cited by this paper
• Molecular analysis of diffuse intrinsic brainstem gliomas in adults

  2013cited by this paper
• Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy – Results of a United Kingdom phase II trial (CNS 2007 04)

  2013cited by this paper
• Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.

  2013cited by this paper
• Clinical characteristics and treatment of malignant brainstem gliomas in elderly patients

  2013cited by this paper
• A case of pleomorphic xanthoastrocytoma with anaplastic features in the pineal gland

  2013cited by this paper
• Temozolomide for high grade glioma.

  2013cited by this paper
• Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

  2012cited by this paper
• Adult brainstem gliomas.

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• Bevacizumab and daily temozolomide for recurrent glioblastoma

  2012cited by this paper
• Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

  2012cited by this paper
• Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma

  2011cited by this paper
• Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group.

  2011cited by this paper
• Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma.

  2011cited by this paper
• Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.

  2011cited by this paper
• Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.

  2010cited by this paper
• Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.

  2010cited by this paper
• 2007 World Health Organization classification of tumours of the central nervous system

  2009cited by this paper
• Cerebellar pilocytic astrocytoma: a treatment protocol based upon analysis of 73 cases and a review of the literature

  2009cited by this paper
• UvA-DARE ( Digital Academic Repository ) Angiogenesis inhibition in high grade glioma Verhoeff

  2009cited by this paper
• NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

  2009cited by this paper
• Natural history and management of brainstem gliomas in adults

  2008cited by this paper
• Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.

  2008cited by this paper
• Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience

  2008cited by this paper
• Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

  2007cited by this paper
• Temozolomide in pediatric low‐grade glioma

  2007cited by this paper
• Temozolomide in children with progressive low-grade glioma.

  2007cited by this paper
• The 2007 WHO Classification of Tumours of the Central Nervous System

  2007cited by this paper
• Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

  2006cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Central nervous system cancers.

  2005cited by this paper
• A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.

  2002cited by this paper
• Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.

  2000cited by this paper
• Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.

  1997cited by this paper
• Recurrence patterns and anaplastic change in a long-term study of pilocytic astrocytomas.

  1997cited by this paper
• Plasma and tissue disposition of mitozolomide in mice.

  1986cited by this paper

• Recent advances in immunotherapy for gliomas: overcoming barriers and advancing precision strategies

  2026cites this paper
• Development of AGT-7: An Innovative 99mTc-Labeled Theranostic Platform for Glioblastoma Imaging and Therapy

  2025cites this paper
• Advanced control models for glioblastoma multiforme management: optimizing drug therapies and adaptive tumor volume regulation with fractional-order mathematical modeling

  2025cites this paper
• Recent in vitro models and tissue engineering strategies to study glioblastoma

  2024cites this paper
• Complement and coagulation cascades are associated with prognosis and the immune microenvironment of lower-grade glioma

  2024cites this paper
• Beyond The Tumor: A Review of Standard Procedures and Emerging Advancements in Treatments for Glioblastomas

  2024cites this paper
• Targeting DNA Repair Pathways in Orthotopic Glioblastoma Xenoplants

  2024cites this paper
• Stemness subtypes in lower-grade glioma with prognostic biomarkers, tumor microenvironment, and treatment response

  2024cites this paper
• Ginsenoside RK3 inhibits glioblastoma by modulating macrophage M2 polarization via the PPARG/CCL2 axis.

  2024cites this paper
• A Synergistic Semaglutide-targeted Fluorescent Nanodrug Delivery System and its Therapeutic Efficacy in Diabetic Nephropathy Treatment

  2024cites this paper
• Radiotherapy and radio‐sensitization in H3 K27M ‐mutated diffuse midline gliomas

  2023cites this paper
• Extensive Leptomeningeal Spreading of Ependymoma in an Adult: Case Report and Literature Review

  2023cites this paper
• Decoding Diffuse Midline Gliomas: A Comprehensive Review of Pathogenesis, Diagnosis and Treatment

  2023cites this paper
• Drug-Loaded Lipid Magnetic Nanoparticles for Combined Local Hyperthermia and Chemotherapy against Glioblastoma Multiforme

  2023cites this paper
• Network pharmacology and experimental verification reveal the mechanism of safranal against glioblastoma (GBM)

  2023cites this paper
• Glucosylceramide Synthase Inhibitors Induce Ceramide Accumulation and Sensitize H3K27 Mutant Diffuse Midline Glioma to Irradiation

  2023cites this paper
• Targeting IGF2BP3 in Cancer

  2023cites this paper
• Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas

  2023cites this paper
• Rare Neuronal, Glial and Glioneuronal Tumours in Adults

  2023cites this paper
• Synthesis and Antiproliferative Evaluation of New 1,3,5‐Trisubstituted 1,2,4‐Triazole Derivatives against Glioblastoma Cell Lines

  2023cites this paper
• Identification and verification of the temozolomide resistance feature gene DACH1 in gliomas

  2023cites this paper
• Engineered extracellular vesicles (EVs): Promising diagnostic/therapeutic tools for pediatric high-grade glioma.

  2023cites this paper
• New Directions in the Therapy of Glioblastoma

  2022cites this paper
• Advances of DNA Damage Repair-Related Drugs and Combination With Immunotherapy in Tumor Treatment

  2022cites this paper
• IP-Se-06, a Selenylated Imidazo[1,2-a]pyridine, Modulates Intracellular Redox State and Causes Akt/mTOR/HIF-1α and MAPK Signaling Inhibition, Promoting Antiproliferative Effect and Apoptosis in Glioblastoma Cells

  2022cites this paper
• Contemporary outcomes of diffuse leptomeningeal glioneuronal tumor in pediatric patients: A case series and literature review.

  2022cites this paper
• Therapeutic Options in Neuro-Oncology

  2022cites this paper
• Clinical efficacy of early postoperative intensity-modulated radiotherapy combined with Temozolomide chemotherapy in the treatment of patients with malignant glioma

  2022cites this paper
• SU4312 Represses Glioma Progression by Inhibiting YAP and Inducing Sensitization to the Effect of Temozolomide

  2022cites this paper
• Rewired Metabolism of Amino Acids and Its Roles in Glioma Pathology

  2022cites this paper
• Neoantigen Vaccines; Clinical Trials, Classes, Indications, Adjuvants and Combinatorial Treatments

  2022cites this paper
• Comparative Activity of Chlonisol and Temozolomide in Mice After Intracranial Transplantation of Ehrlich Carcinoma and HER2-Positive Breast Cancer

  2022cites this paper
• NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity

  2022cites this paper
• ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism

  2021cites this paper
• Title Page Title: Functional implications of aging-related lncRNAs for predicting prognosis and immune status in glioma patients Running Title: Aging-related lncRNAs and glioma Authors and affiliations

  2021cites this paper
• glioma cells by inhibiting long noncoding RNA FOXD 2 ‐ As 1 ‐ promoted EZH 2 activation

  2021cites this paper
• Curcumol inhibits malignant biological behaviors and TMZ-resistance in glioma cells by inhibiting long noncoding RNA FOXD2-As1-promoted EZH2 activation

  2021cites this paper
• Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma

  2021cites this paper
• Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia

  2021cites this paper
• RETRACTED ARTICLE: GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death

  2021cites this paper
• Curcumol inhibits malignant biological behaviors and TMZ-resistance of glioma cells via reducing long noncoding RNA FoxD2-As1 promoted EZH2 activation

  2021cites this paper
• Arginase-1+ Exosomes from Reprogrammed Macrophages Promote Glioblastoma Progression

  2020cites this paper
• Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal®) in glioma patients in China

  2020cites this paper
• Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/ZIC5 Axis in Glioma

  2020cites this paper
• Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics

  2020cites this paper
• CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model

  2020cites this paper
• Evaluation of inhibitory effects of flavonoids on breast cancer resistance protein (BCRP): From library screening to biological evaluation to structure-activity relationship.

  2019cites this paper
• Long non-coding RNA SNHG5 promotes glioma progression via miR-205/E2F3 axis

  2019cites this paper
• Cytotoxic impact of a perillyl alcohol–temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro

  2019cites this paper
• FoxD2-AS1 is a prognostic factor in glioma and promotes temozolomide resistance in a O6-methylguanine-DNA methyltransferase-dependent manner

  2019cites this paper
• Development of AGT-7 An Innovative 99mTc-Labeled Theranostic Platform for Glioblastoma Imaging and Therapy

  year unknowncites this paper